Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes

As an emerging antitumor strategy, immune checkpoint therapy is one of the most promising anticancer therapies due to its long response duration. Antibodies against the programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) axis have been extensively applied to various cancers and have demo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Dan, Hou, Xiaolin, Yu, Jing, He, Xiujing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355550/
https://www.ncbi.nlm.nih.gov/pubmed/35935874
http://dx.doi.org/10.3389/fphar.2022.928369
_version_ 1784763319734763520
author Zheng, Dan
Hou, Xiaolin
Yu, Jing
He, Xiujing
author_facet Zheng, Dan
Hou, Xiaolin
Yu, Jing
He, Xiujing
author_sort Zheng, Dan
collection PubMed
description As an emerging antitumor strategy, immune checkpoint therapy is one of the most promising anticancer therapies due to its long response duration. Antibodies against the programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) axis have been extensively applied to various cancers and have demonstrated unprecedented efficacy. Nevertheless, a poor response to monotherapy with anti-PD-1/PD-L1 has been observed in metastatic breast cancer. Combination therapy with other standard treatments is expected to overcome this limitation of PD-1/PD-L1 blockade in the treatment of breast cancer. In the present review, we first illustrate the biological functions of PD-1/PD-L1 and their role in maintaining immune homeostasis as well as protecting against immune-mediated tissue damage in a variety of microenvironments. Several combination therapy strategies for the combination of PD-1/PD-L1 blockade with standard treatment modalities have been proposed to solve the limitations of anti-PD-1/PD-L1 treatment, including chemotherapy, radiotherapy, targeted therapy, antiangiogenic therapy, and other immunotherapies. The corresponding clinical trials provide valuable estimates of treatment effects. Notably, several combination options significantly improve the response and efficacy of PD-1/PD-L1 blockade. This review provides a PD-1/PD-L1 clinical trial landscape survey in breast cancer to guide the development of more effective and less toxic combination therapies.
format Online
Article
Text
id pubmed-9355550
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93555502022-08-06 Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes Zheng, Dan Hou, Xiaolin Yu, Jing He, Xiujing Front Pharmacol Pharmacology As an emerging antitumor strategy, immune checkpoint therapy is one of the most promising anticancer therapies due to its long response duration. Antibodies against the programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) axis have been extensively applied to various cancers and have demonstrated unprecedented efficacy. Nevertheless, a poor response to monotherapy with anti-PD-1/PD-L1 has been observed in metastatic breast cancer. Combination therapy with other standard treatments is expected to overcome this limitation of PD-1/PD-L1 blockade in the treatment of breast cancer. In the present review, we first illustrate the biological functions of PD-1/PD-L1 and their role in maintaining immune homeostasis as well as protecting against immune-mediated tissue damage in a variety of microenvironments. Several combination therapy strategies for the combination of PD-1/PD-L1 blockade with standard treatment modalities have been proposed to solve the limitations of anti-PD-1/PD-L1 treatment, including chemotherapy, radiotherapy, targeted therapy, antiangiogenic therapy, and other immunotherapies. The corresponding clinical trials provide valuable estimates of treatment effects. Notably, several combination options significantly improve the response and efficacy of PD-1/PD-L1 blockade. This review provides a PD-1/PD-L1 clinical trial landscape survey in breast cancer to guide the development of more effective and less toxic combination therapies. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9355550/ /pubmed/35935874 http://dx.doi.org/10.3389/fphar.2022.928369 Text en Copyright © 2022 Zheng, Hou, Yu and He. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zheng, Dan
Hou, Xiaolin
Yu, Jing
He, Xiujing
Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
title Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
title_full Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
title_fullStr Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
title_full_unstemmed Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
title_short Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
title_sort combinatorial strategies with pd-1/pd-l1 immune checkpoint blockade for breast cancer therapy: mechanisms and clinical outcomes
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355550/
https://www.ncbi.nlm.nih.gov/pubmed/35935874
http://dx.doi.org/10.3389/fphar.2022.928369
work_keys_str_mv AT zhengdan combinatorialstrategieswithpd1pdl1immunecheckpointblockadeforbreastcancertherapymechanismsandclinicaloutcomes
AT houxiaolin combinatorialstrategieswithpd1pdl1immunecheckpointblockadeforbreastcancertherapymechanismsandclinicaloutcomes
AT yujing combinatorialstrategieswithpd1pdl1immunecheckpointblockadeforbreastcancertherapymechanismsandclinicaloutcomes
AT hexiujing combinatorialstrategieswithpd1pdl1immunecheckpointblockadeforbreastcancertherapymechanismsandclinicaloutcomes